Sam-A Pharm. Co. Ltd Market Cap ($56.13 Million)
Market Cap & Net Worth: Sam-A Pharm. Co. Ltd (009300)
Sam-A Pharm. Co. Ltd market cap. Sam-A Pharm. Co. Ltd (KQ:009300) has a market capitalization of $56.13 Million (₩82.82 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #21246 globally and #1242 in its home market, demonstrating a -1.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sam-A Pharm. Co. Ltd's stock price ₩13570.00 by its total outstanding shares 6103340 (6.10 Million). Also see how efficiently does Sam-A Pharm. Co. Ltd generate cash for how efficiently the company converts equity into cash flow.
Sam-A Pharm. Co. Ltd Market Cap History (2015–2026)
Sam-A Pharm. Co. Ltd market cap history from 2015 to 2026. Data shows growth from $53.97 Million to $56.13 Million (1.30% CAGR). Check Sam-A Pharm. Co. Ltd stock price for real-time trading data and today's change.
Index Memberships
Sam-A Pharm. Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.03% | #567 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.03% | #567 of 1384 |
Weight: Sam-A Pharm. Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sam-A Pharm. Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sam-A Pharm. Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 009300 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Sam-A Pharm. Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Sam-A Pharm. Co. Ltd's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $78.76 Million | $65.88 Billion | $9.87 Billion | 0.00x | 0.01x |
| 2017 | $59.54 Million | $61.79 Billion | $5.80 Billion | 0.00x | 0.01x |
| 2018 | $59.21 Million | $66.95 Billion | $8.80 Billion | 0.00x | 0.01x |
| 2019 | $60.93 Million | $71.56 Billion | $10.20 Billion | 0.00x | 0.01x |
| 2020 | $64.39 Million | $53.65 Billion | $123.85 Million | 0.00x | 0.52x |
| 2021 | $76.26 Million | $54.67 Billion | $3.39 Billion | 0.00x | 0.02x |
| 2022 | $67.21 Million | $81.70 Billion | $11.91 Billion | 0.00x | 0.01x |
| 2023 | $67.83 Million | $97.21 Billion | $21.37 Billion | 0.00x | 0.00x |
| 2024 | $69.12 Million | $95.58 Billion | $22.08 Billion | 0.00x | 0.00x |
| 2025 | $64.98 Million | $77.80 Billion | $12.94 Billion | 0.00x | 0.01x |
Competitor Companies of 009300 by Market Capitalization
Companies near Sam-A Pharm. Co. Ltd in the global market cap rankings as of November 4, 2026. Also see 009300 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Sam-A Pharm. Co. Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5272 globally with a market cap of $2.49 Billion USD ( ₩3.67 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8989 globally with a market cap of $902.70 Million USD ( ₩1.33 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9557 globally with a market cap of $793.12 Million USD ( ₩1.17 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10371 globally with a market cap of $674.16 Million USD ( ₩994.80 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5272 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.49 Billion | ₩171400.00 |
| #8989 | ST Pharm Co.Ltd | KQ:237690 | $902.70 Million | ₩71400.00 |
| #9557 | NatureCell Co.Ltd | KQ:007390 | $793.12 Million | ₩22050.00 |
| #10371 | Oscotec Inc | KQ:039200 | $674.16 Million | ₩35400.00 |
Market Capitalization of Sam-A Pharm. Co. Ltd (2015–2026)
Market capitalization of Sam-A Pharm. Co. Ltd from 2015 to today. Between 2015 and today, Sam-A Pharm. Co. Ltd's market cap moved from $53.97 Million to $ 56.13 Million, with a yearly change of 1.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩56.13 Million | -13.62% |
| 2025 | ₩64.98 Million | -5.98% |
| 2024 | ₩69.12 Million | +1.89% |
| 2023 | ₩67.83 Million | +0.93% |
| 2022 | ₩67.21 Million | -11.87% |
| 2021 | ₩76.26 Million | +18.44% |
| 2020 | ₩64.39 Million | +5.68% |
| 2019 | ₩60.93 Million | +2.90% |
| 2018 | ₩59.21 Million | -0.56% |
| 2017 | ₩59.54 Million | -24.40% |
| 2016 | ₩78.76 Million | +45.93% |
| 2015 | ₩53.97 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Sam-A Pharm. Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $56.13 Million USD |
| MoneyControl | $56.13 Million USD |
| MarketWatch | $56.13 Million USD |
| marketcap.company | $56.13 Million USD |
| Reuters | $56.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sam-A Pharm. Co. Ltd
Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea. The company offers a range of pharmaceutical products in the areas of respiratory, anti-biotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, a… Read more